The role of gender and sex hormones in determining the onset and outcome of multiple sclerosis

Multiple Sclerosis Journal

Volumn 20, Issue 5, 2014, Pages 520-526

  Bove, Riley ^a,b   Chitnis, Tanuja ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Clinically isolated syndrome; demyelination; gender; genetics; hormonal regulation; inflammation; multiple sclerosis; pregnancy; sex differences; sex hormones; sexual development

Indexed keywords

ANDROGEN; ANDROSTANOLONE; BETA1A INTERFERON; CONTRACEPTIVE AGENT; ESTRADIOL; ESTRIOL; ESTROGEN; GESTAGEN; GLATIRAMER; HLA ANTIGEN; NATALIZUMAB; PROGESTERONE; SEX HORMONE; TESTOSTERONE; TUMOR NECROSIS FACTOR ALPHA; INTERFERON;

BREAST FEEDING; CD4+ T LYMPHOCYTE; CLINICAL OBSERVATION; COGNITIVE DEFECT; DEMYELINATING DISEASE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE PREDISPOSITION; ENVIRONMENTAL CHANGE; EXPERIMENTAL STUDY; FEMALE; GENDER AND SEX; GENETIC RISK; HERITABILITY; HIGH RISK PATIENT; HORMONAL CONTRACEPTION; HORMONE SUBSTITUTION; HUMAN; MALE; MENOPAUSE; META ANALYSIS (TOPIC); MULTIPLE SCLEROSIS; NONHUMAN; ONSET AGE; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PREGNANCY; PUBERTY; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SEX RATIO; CULTURAL FACTOR; PATHOGENESIS; ENVIRONMENT; GENETIC PREDISPOSITION; GENETICS; HEREDITY; METABOLISM; PHENOTYPE; SEXUAL DEVELOPMENT;

AGE OF ONSET; CULTURAL CHARACTERISTICS; DISEASE PROGRESSION; ENVIRONMENT; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GONADAL STEROID HORMONES; HEREDITY; HUMANS; MALE; MULTIPLE SCLEROSIS; PHENOTYPE; RISK ASSESSMENT; RISK FACTORS; SEX CHARACTERISTICS; SEX FACTORS; SEXUAL DEVELOPMENT;

EID: 84899070133     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458513519181     Document Type: Review

References (50)

1. Trojano M, Lucchese G, Graziano G, et al. Geographical variations in sex ratio trends over time in multiple sclerosis. PLoS One. 2012 ; 7: e48078
2. Maghzi AH, Ghazavi H, Ahsan M, et al. Increasing female preponderance of multiple sclerosis in Isfahan, Iran: A population-based study. Mult Scler. 2010 ; 16: 359-361
3. Ramagopalan SV, Dyment DA, Herrera BM, et al. Clustering of autoimmune disease in families at high risk for multiple sclerosis?. Lancet Neurol. 2007 ; 6: 206-207
4. Markle JG, Frank DN, Mortin-Toth S, et al. Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity. Science. 2013 ; 339: 1084-1088
5. Krementsov DN, Noubade R, Dragon JA, et al. Sex-specific control of CNS autoimmunity by p38 MAPK signaling in myeloid cells. Ann Neurol. 2013 ;:
6. Correale J, Balbuena Aguirre ME, Farez MF. Sex-specific environmental influences affecting MS development. Clin Immunol. 2013 ; 149: 176-181
7. Spach KM, Hayes CE. Vitamin D3 confers protection from autoimmune encephalomyelitis only in female mice. J Immunol ; 2005 ; 2005. 4119.
8. Munger KL, Chitnis T, Ascherio A. Body size and risk of MS in two cohorts of US women. Neurology. 2009 ; 73: 1543-1550
9. Marrie RA, Horwitz RI, Cutter G, et al. Association between comorbidity and clinical characteristics of MS. Acta Neurol Scand. 2011 ; 124: 135-141
10. Nielsen TR, Pedersen M, Rostgaard K, et al. Correlations between Epstein-Barr virus antibody levels and risk factors for multiple sclerosis in healthy individuals. Mult Scler. 2007 ; 13: 420-423
11. Sadovnick AD. Differential effects of genetic susceptibility factors in males and females with multiple sclerosis. Clin Immunol. 2013 ; 149: 170-175
12. Zoccolella S, Tortorella C, Iaffaldano P, et al. Low serum urate levels are associated to female gender in multiple sclerosis patients. PLoS One. 2012 ; 7: e40608
13. Bove R, Chitnis T. Sexual disparities in the incidence and course of MS. Clin Immunol. 2013 ; 149 (2). 201-10
14. Multiple sclerosis risk after optic neuritis: Final optic neuritis treatment trial follow-up. Arch Neurol. 2008 ; 65: 727-732
15. Lebrun C, Le Page E, Kantarci O, et al. Impact of pregnancy on conversion to clinically isolated syndrome in a radiologically isolated syndrome cohort. Mult Scler. 2012 ; 18: 1297-1302
16. Dobson R, Ramagopalan S, Giovannoni G. The effect of gender in clinically isolated syndrome (CIS): A meta-analysis. Mult Scler. 2012 ; 18: 600-604
17. Paty DW, Noseworthy JH, Ebers GC Multiple sclerosis. Paty DW Ebers GC, ed. Philadelphia: FA Davis Company ; 1997: 48-51.
18. Confavreux C, Compston A McAlpine's Multiple Sclerosis. 4 th ed. Edinburgh: Churchill Livingstone, 2006, pp. 183-272. Edinburgh: Churchill Livingstone ; 2006: 183-272.
19. Tremlett H, Zhao Y, Joseph J, et al. Relapses in multiple sclerosis are age- and time-dependent. J Neurol Neurosurg Psychiatry. 2008 ; 79: 1368-1374
20. Benedict RH, Zivadinov R. Risk factors for and management of cognitive dysfunction in multiple sclerosis. Nat Rev Neurol. 2011 ; 7: 332-342
21. Savettieri G, Messina D, Andreoli V, et al. Gender-related effect of clinical and genetic variables on the cognitive impairment in multiple sclerosis. J Neurol. 2004 ; 251: 1208-1214
22. Pozzilli C, Tomassini V, Marinelli F, et al. 'Gender gap' in multiple sclerosis: Magnetic resonance imaging evidence. Eur J Neurol. 2003 ; 10: 95-97
23. Fazekas F, Enzinger C, Wallner-Blazek M, et al. Gender differences in MRI studies on multiple sclerosis. J Neurol Sci. 2009 ; 286: 28-30
24. Schoonheim MM, Hulst HE, Landi D, et al. Gender-related differences in functional connectivity in multiple sclerosis. Mult Scler. 2012 ; 18: 164-173
25. Rudick RA, Kappos L, Kinkel R, et al. Gender effects on intramuscular interferon beta-1a in relapsing-remitting multiple sclerosis: Analysis of 1406 patients. Mult Scler. 2011 ; 17: 353-360
26. Wolinsky JS, Shochat T, Weiss S, et al. Glatiramer acetate treatment in PPMS: Why males appear to respond favorably. J Neurol Sci. 2009 ; 286: 92-98
27. Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results. Neurology. 2001 ; 56: 1496-1504
28. Hutchinson M, Kappos L, Calabresi PA, et al. The efficacy of natalizumab in patients with relapsing multiple sclerosis: Subgroup analyses of AFFIRM and SENTINEL. J Neurol. 2009 ; 256: 405-415
29. Gold SM, Voskuhl RR. Estrogen and testosterone therapies in multiple sclerosis. Progr Brain Res. 2009 ; 175: 239-251
30. Chitnis T. Role of puberty in multiple sclerosis risk and course. Clin Immunol. 2013 ; 149: 192-200
31. Kennedy J, O'Connor P, Sadovnick AD, et al. Age at onset of multiple sclerosis may be influenced by place of residence during childhood rather than ancestry. Neuroepidemiology. 2006 ; 26: 162-167
32. Holmqvist P, Hammar M, Landtblom AM, et al. Age at onset of multiple sclerosis is correlated to use of combined oral contraceptives and childbirth before diagnosis. Fertil Steril. 2010 ; 94: 2835-2837
33. Kotzamani D, Panou T, Mastorodemos V, et al. Rising incidence of multiple sclerosis in females associated with urbanization. Neurology. 2012 ; 78: 1728-1735
34. Confavreux C, Hutchinson M, Hours MM, et al. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med. 1998 ; 339: 285-291
35. Sicotte NL, Liva SM, Klutch R, et al. Treatment of multiple sclerosis with the pregnancy hormone estriol. Ann Neurol. 2002 ; 52: 421-428
36. Vukusic S, Ionescu I, El-Etr M, et al. The Prevention of Post-Partum Relapses with Progestin and Estradiol in Multiple Sclerosis (POPART'MUS) trial: Rationale, objectives and state of advancement. J Neurol Sci. 2009 ; 286: 114-118
37. D'Hooghe MB, Nagels G, Uitdehaag BM. Long-term effects of childbirth in MS. J Neurol Neurosurg Psychiatry. 2010 ; 81: 38-41
38. Hedstrom A, Hillert J, Olsson T, et al. Reverse causality behind the association between reproductive history and MS. Mult Scler. 2013 ;:
39. Magyari M, Koch-Henriksen N, Pfleger CC, et al. Reproduction and the risk of multiple sclerosis. Mult Scler. 2013 ; 19: 1604-1609
40. Langer-Gould A, Beaber BE. Effects of pregnancy and breastfeeding on the multiple sclerosis disease course. Clin Immunol. 2013 ; 149 (2). 244-50
41. Pakpoor J, Disanto G, Lacey MV, et al. Breastfeeding and multiple sclerosis relapses: A meta-analysis. J Neurol. 2012 ; 259: 2246-2248
42. Holmqvist P, Hammar M, Landtblom AM, et al. Symptoms of multiple sclerosis in women in relation to cyclical hormone changes. Eur J Contracept Reprod Health Care. 2009 ; 14: 365-370
43. Alonso A, Clark CJ. Oral contraceptives and the risk of multiple sclerosis: A review of the epidemiologic evidence. J Neurol Sci. 2009 ; 286: 73-75
44. D'Hooghe MB, Haentjens P, Nagels G, et al. Menarche, oral contraceptives, pregnancy and progression of disability in relapsing onset and progressive onset multiple sclerosis. J Neurol. 2012 ; 259: 855-861
45. Bove R. Autoimmune diseases and reproductive aging. Clin Immunol. 2013 ; 149: 251-264
46. Bove RM, Healy B, Augustine A, et al. Effect of gender on late-onset multiple sclerosis. Mult Scler. 2012 ; 18: 1472-1479
47. Liva SM, Voskuhl RR. Testosterone acts directly on CD4+ T lymphocytes to increase IL-10 production. J Immunol. 2001 ; 167: 2060-2067
48. Pines A. Male menopause: Is it a real clinical syndrome?. Climacteric. 2011 ; 14: 15-17
49. Tomassini V, Onesti E, Mainero C, et al. Sex hormones modulate brain damage in multiple sclerosis: MRI evidence. J Neurol Neurosurg Psychiatry. 2005 ; 76: 272-275
50. Sicotte NL, Giesser BS, Tandon V, et al. Testosterone treatment in multiple sclerosis: A pilot study. Arch Neurol. 2007 ; 64: 683-688